Compare · CDIO vs IDXX
CDIO vs IDXX
Side-by-side comparison of Cardio Diagnostics Holdings Inc. (CDIO) and IDEXX Laboratories Inc. (IDXX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CDIO and IDXX operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- IDXX carries a market cap of $41.47B.
- IDXX has been more active in the news (2 items in the past 4 weeks vs 1 for CDIO).
- IDXX has more recent analyst coverage (23 ratings vs 0 for CDIO).
- Company
- Cardio Diagnostics Holdings Inc.
- IDEXX Laboratories Inc.
- Price
- -
- -
- Market cap
- -
- $41.47B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- 1991
- News (4w)
- 1
- 2
- Recent ratings
- 0
- 23
IDEXX Laboratories Inc.
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Latest CDIO
- IBN Initiates Coverage of Cardio Diagnostics Holdings Inc.
- SEC Form 4 filed by Fung Peter K
- SEC Form 4 filed by Betts Wendy J
- SEC Form 4 filed by Intrater James
- SEC Form 4 filed by Burton Paul Frederick
- SEC Form 10-K filed by Cardio Diagnostics Holdings Inc.
- Cardio Diagnostics Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Cardio Diagnostics Holdings, Inc. to Host Investor Call on Wednesday, February 18, 2026
- Cardio Diagnostics, Aimil Ltd. and Dr. Lal PathLabs Limited Partner to Launch the PrecisionCHD™ Test in India
- SEC Form 4 filed by Director Fung Peter K
Latest IDXX
- Citigroup initiated coverage on IDEXX Labs with a new price target
- IDEXX Laboratories to Release 2026 First Quarter Financial Results
- IDEXX Announces UK Availability of Cancer Dx Panel for Early Detection of Canine Lymphoma
- SEC Form DEFA14A filed by IDEXX Laboratories Inc.
- SEC Form DEF 14A filed by IDEXX Laboratories Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by IDEXX Laboratories Inc.
- IDEXX Laboratories Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- SEC Form PRE 14A filed by IDEXX Laboratories Inc.
- EVP, GC & Corporate Secretary Underberg Sharon E. exercised 197 shares at a strike of $505.53, increasing direct ownership by 3% to 7,138 units (SEC Form 4)
- Executive Vice President Hunt Nimrata sold $1,115,577 worth of shares (1,758 units at $634.57), decreasing direct ownership by 9% to 18,141 units (SEC Form 4)